GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Intangible Assets

Humanigen (Humanigen) Intangible Assets : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Humanigen Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Humanigen's intangible assets for the quarter that ended in Mar. 2023 was $0.00 Mil.


Humanigen Intangible Assets Historical Data

The historical data trend for Humanigen's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Intangible Assets Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Humanigen Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Humanigen  (OTCPK:HGENQ) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Humanigen Intangible Assets Related Terms

Thank you for viewing the detailed overview of Humanigen's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen (Humanigen) Business Description

Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
Dale Chappell 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne officer: Chief Medical Officer 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant director 90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan officer: Chief Commercial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie director C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd. 10 percent owner C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd. 10 percent owner C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton director 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd. 10 percent owner P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester officer: Chief Financial Officer C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022

Humanigen (Humanigen) Headlines

From GuruFocus